Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Diluent Recommendation: Reconstitute with bacteriostatic water or a suitable research-grade diluent
TIRZEPATIDE For research use only
Muscle, tendon, and ligament repair: Accelerated healing of tendon and ligament injuries, improved muscle regeneration, and enhanced biomechanical strength, with higher local levels of growth factors such as VEGF, bFGF, and EGF in healing tissues
US$ 22.59
US$ 23.34
US$ 20.43
US$ 29.52
US$ 27.48
US$ 27.78
US$ 21.11
US$ 23.52
US$ 24.37
US$ 25.37
US$ 22.63
US$ 27.65
US$ 21.43
